Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
العنوان: | Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy |
---|---|
المؤلفون: | L. Regolo, Giovanna Chiorino, C Ghimenti, Alberto Zambelli, Maria Scatolini, Maurizia Mello-Grand, Enrico Grosso |
المصدر: | Experimental and Therapeutic Medicine |
بيانات النشر: | D.A. Spandidos, 2012. |
سنة النشر: | 2012 |
مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Anastrozole, aromatase inhibitors, Breast cancer, aromatase targeting microRNAs, Immunology and Microbiology (miscellaneous), Internal medicine, microRNA, medicine, breast neoplasms, genetic polymorphism, Aromatase, Neoadjuvant therapy, biology, Oncogene, business.industry, Cancer, General Medicine, Articles, medicine.disease, Molecular medicine, intrinsic resistance, Endocrinology, biology.protein, Cancer research, business, medicine.drug |
الوصف: | Aromatase inhibitors (AIs), such as anastrozole, are established in the treatment of hormone-dependent breast cancer. However, ∼20% of patients with hormone receptor-positive breast tumors treated with anastrozole do not respond and it remains impossible to accurately predict sensitivity. Since polymorphisms in the aromatase gene may influence the response to inhibitory drugs, we evaluated the presence of rs6493497 and rs7176005 polymorphisms (mapping in the 5′-flanking region of the CYP19A1 gene coding for the aromatase protein) in a cohort of 37 patients with postmenopausal breast cancer who received three-month neoadjuvant treatment with anastrozole. We then investigated any association of the polymorphisms with changes in aromatase mRNA expression change and/or response to treatment. We also analyzed five miRNAs computationally predicted to target aromatase, to observe any association between their expression and sensitivity to anastrozole. Three samples carried the two polymorphisms and the remaining samples were wild-type for both, however, no association with response or with aromatase mRNA basal expression level or expression difference after therapy was observed. Polymorphic samples that were resistant to anastrozole showed no change or decrease in aromatase expression following AI treatment, whereas an increase in expression was observed for the polymorphic responsive samples. No statistically significant correlation was observed between miRNA and aromatase mRNA expression, or with response to anastrozole neoadjuvant treatment. These data indicate that the polymorphisms analyzed are not involved in aromatase activity and that other epigenetic mechanisms may regulate aromatase protein expression. |
اللغة: | English |
تدمد: | 1792-1015 1792-0981 |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312b0d14c026b928dfd40ea54e6ba6a9Test http://europepmc.org/articles/PMC3570232Test |
حقوق: | OPEN |
رقم الانضمام: | edsair.doi.dedup.....312b0d14c026b928dfd40ea54e6ba6a9 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 17921015 17920981 |
---|